



Department of Pharmaceuticals
Ministry of Chemicals and Fertilizers
Government of India



Confederation of Indian Industry

13th National Pharmaceutical Conclave
"Make, Develop and Innovate in India"

19 April 2016 : Hotel Le Meridien, New Delhi

Suggested Programme

0930-1045 Hrs	Inaugural Session
Welcome Address	Ms Amita Sarkar Deputy Director General Confederation of Indian Industry (CII)
Setting the Context	Dr Rajiv I Modi Chairman, CII National Committee on Pharma CMD, Cadila Pharmaceuticals Ltd
Industry perspective	Mr K G Ananthkrishnan Co-Chairman, CII National Committee on Pharma MD, MSD Pharmaceuticals Ltd.
Special Address	Dr V K Subburaj Secretary Department of Pharmaceuticals Ministry of Chemicals and Fertilizers
Keynote Address	Mr Amitabh Kant CEO NITI Aayog
Inaugural Address by Chief Guest	Mr Hansraj Ahir Minister of State Department of Pharmaceuticals Ministry of Chemicals and Fertilizers
Closing Remarks	Dr Murtaza Khorakiwala Co-Chairman, CII National Committee on Pharma MD, Wockhardt Ltd.

1045-1100 Hrs

Networking Tea / Coffee

1100-1200 Hrs

India: Pharmacy to the world for High Quality medicines

India has taken the leadership position in manufacturing of medicines as well as supply to the regulated and non-regulated markets. This session would focus on what would it take India to maintain and cement its position as the provider of high quality medicines to the world.

Session Moderator

Dr K Vijayaraghavan
Chairman
Sathguru Management Consultants

Panelists

Dr Rajiv I Modi
Chairman, CII National Committee on Pharma
CMD, Cadila Pharmaceuticals Ltd

Mr Prashant Kumar Pathak
CEO & MD
Delcure Lifesciences Limited

Mr Gaurav Sharma
Director, Manufacturing Operations
Abbott Healthcare Pvt. Ltd.

Special Address

Mr K L Sharma
Joint Secretary
Ministry of Health and Family Welfare

Special Address

Mr Anup Wadhawan
Director General of Foreign Trade (DGFT)

Concluding Remarks

Dr K Vijayaraghavan
Chairman
Sathguru Management Consultants

Q&A

1200-1300 Hrs

R&D opportunity in Bio-Pharma and Biologicals in India

The Research and Development in the context of an innovation ecosystem in India is unique and evolving in nature. This session will look at the components of an innovation ecosystem, areas where there is a clear advantage - Bio-Pharma and Biologicals . It is not enough to partner but also to start the journey on the road to innovation.

Session Moderator

Mr Nick Mitchell

Co-Convenor of the Telangana State Life Sciences and Health Care Panel, CII
Managing Director, Phenomenex India

Panelists

Dr Murtaza Khorakiwala

Co-Chairman, CII National Committee on Pharma MD, Wockhardt Ltd.

Dr Arun Chandavarkar

CEO & Joint Managing Director
Biocon Ltd.

Mr Gajanan Nabar

Managing Director
Praj Industries Ltd.

Address

Dr V G Somani

Joint Drugs Controller (India)
Central Drugs Standard Control Organization
(CDSCO)

Special Address

Dr K Vijay Raghavan

Secretary
Department of Biotechnology
Ministry of Science & Technology

Closing Remarks

Mr Nick Mitchell

Co-Convenor of the Telangana State Life Sciences and Health Care Panel, CII
Managing Director, Phenomenex India

1300-1400 Hrs

Networking Lunch

1400-1500 Hrs

Evolution of FDCs

The development of fixed-dose combinations (FDCs) is becoming increasingly important from a public health perspective. Such combinations of drugs are being used in the treatment of a wide range of conditions and are particularly useful in the management of HIV/AIDS, malaria and tuberculosis, which are considered to be the foremost infectious disease threats in the world today. FDCs' popularity in India is due to advantages such as increased efficacy, better compliance, reduced cost and simpler logistics of distribution. Recently, Indian government has decided to prohibit manufacturing, sale and distribution of FDCs as the said drugs have "no therapeutic justification" and are likely to "involve risk to human beings".

Session Moderator

Mr Vikas Dandekar

Editor - Pharma at ET

Panelists

Dr Rao VSV Vadlamudi

President

Indian Pharmaceutical Association

Dr Y K Gupta

Professor and Head, Department of Pharmacology
All India Institute of Medical Sciences (AIIMS)

Dr R K Sanghavi

Chairman - Medical and Nutraceutical Committee
Indian Drug Manufacturers' Association (IDMA)

Special Address

Mr Sudhansh Pant

Joint Secretary

Department of Pharmaceuticals

Special Address

Dr S Eswara Reddy

Joint Drugs Controller (India)

Central Drugs Standard Control Organization
(CDSCO)

Closing Remarks

Mr Vikas Dandekar

Editor - Pharma at ET

Q&A

1500-1600 Hrs

Accessibility of medicines across all the socio-economic tiers

Access to health care can be defined in a variety of ways. In its most narrow sense, it refers to geographic availability. A far broader definition identifies four dimensions of access: availability, accessibility, affordability, and acceptability. This session will spur a discussion of tackling the broader issue of access that meets Government objectives as well as being economically viable.

Session Moderator

Dr Amar Bhat
President
Two Four Insight Group

Panelists

Mr S Sridhar
Managing Director
Pfizer India Ltd.

Mr Amitava Guha
National Co-conveyor
Jan Swasthya Abhiyan

Dr Girdhar J Gyani
Director General
Association of Healthcare Providers (India)

Mr Bhupendra Singh
Chairman
National Pharmaceutical Pricing Authority (NPPA)

Special Address

Mr M D Sreekumar
CEO
Bureau of Pharma PSUs of India (BPPI)

Keynote Address

Mr K B Aggarwal
Additional secretary
Ministry of Health & Family Welfare

Concluding Remarks

Dr Amar Bhat
President
Two Four Insight Group

Q&A

1600-1615 Hrs

Networking Tea / Coffee

1615-1715 Hrs

Valedictory Session

Strengthening India's API industry for moving up in the global value chain

Welcome Address

Dr Rajiv I Modi

Chairman, CII National Committee on Pharma
CMD, Cadila Pharmaceuticals Ltd

Address

Mr K G Ananthakrishnan

Co-Chairman, CII National Committee on Pharma
MD, MSD Pharmaceuticals Ltd.

Valedictory Address

Mr Hansraj Ahir

Minister of State
Department of Pharmaceuticals
Ministry of Chemicals and Fertilizers

Vote of Thanks

Dr Rajiv I Modi

Chairman, CII National Committee on Pharma
CMD, Cadila Pharmaceuticals Ltd